Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer
Singh P, Ballas L, Sonpavde G, Chen R, Bangs R, Bauman B, Nagar H, Delacroix S, Lerner S, Efstathiou J. Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer. Bladder Cancer 2024, 10: 199-213. PMID: 39493817, PMCID: PMC11530036, DOI: 10.3233/blc-240036.Peer-Reviewed Original ResearchBladder cancer treatmentTransurethral resection of bladder tumorEastern Cooperative Oncology GroupTrimodality therapyLong-term outcomesClinical trialsCancer treatmentRadical cystectomySystemic therapyEligibility criteriaSecondary endpointsTrial eligibility criteriaBladder cancerMaximal transurethral resection of bladder tumorEndpoint definitionsAlternative to radical cystectomyResection of bladder tumorCo-primary end pointsConcurrent systemic therapyMaximal transurethral resectionPhase II/III clinical trialsLocalized bladder cancerEvent-free survivalCooperative Oncology GroupBladder cancer researchCorrelation of urinary comprehensive genomic profile with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605.
St-Laurent M, Plets M, Black P, Singh P, McConkey D, Lucia S, Koshkin V, Stratton K, Bivalacqua T, Kassouf W, Porten S, Bangs R, Tangen C, Thompson I, Meeks J, Caruso V, Phillips K, Bicocca V, Levin T, Lerner S. Correlation of urinary comprehensive genomic profile with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605. Journal Of Clinical Oncology 2024, 42: 529-529. DOI: 10.1200/jco.2024.42.4_suppl.529.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerEvent-free survivalEvent-free survival probabilityComprehensive genomic profilingLow-risk patientsGenomic profilingBCG-unresponsiveRisk scoreBladder cancerHigh riskMolecular response to treatmentImmune checkpoint inhibitionCycles of therapyInvasive bladder cancerEarly treatment intensificationRisk of progressionCycles of treatmentHigh gradeResponse to treatmentTime pointsMolecular responseHG recurrenceIntravenous atezolizumabPersistent CISBladder preservation